International Workshop on the 'On-Off'-Phenomenon in Parkinson’s Disease
New Possibilities for its Management Agno, November 14-16, 1985


52 figures, 42 tables, 3 color plates, 1987
Drug Dosage
The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any change in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.

All rights reserved.
No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center (see "Information for Readers and Subscribers").

© Copyright 1987 by S. Karger AG, P.O. Box, CH-4009 Basel (Switzerland) Printed in Switzerland by Thiir AG Offsetdruck, Pratteln ISBN 3-8055-4692-0

Contents

Foreword .............................................................................................................................. 1

‘On-Off’ Phenomenon: Description, Incidence and Management
Dubuis, R. ...................................................................................................................... 3

Inhibition of Decarboxylase and Levels of Dopa and 3-O-Methylidopa: A Comparative Study of Benserazide versus Carbidopa in Rodents and of Madopar Standard versus Madopar HBS in Volunteers

The Hydrodynamically Balanced System: A Novel Principle of Controlled Drug Release
Erni, W.; Held, K. ........................................................................................................... 21

Single-Dose Pharmacokinetics of Madopar HBS in Patients and Effect of Food and Antacid on the Absorption of Madopar HBS in Volunteers

Bioavailability of L-Dopa after Madopar HBS Administration in Healthy Volunteers
Crevoisier, C; Hoevels, B.; Zurcher, G.; Da Prada, M. .............................................................................. 36

Discussion ...................................................................................................................... 47

Single-Dose Studies of a Slow-Release Preparation of Levodopa and Benserazide (Madopar HBS) in Parkinson’s Disease
Marion, M.H.; Stocchi, F.; Malcolm, S.L.; Quinn, N.P.; Jenner, P.; Marsden, C.D .......................................... 54

Substitution of Standard Madopar by Madopar HBS in Parkinsonians with Fluctuations
Chouza, C; Romero, S.; Medina, O.de; Aljanati, R.; Scarfelli, A.; Caamano, J.L.; Panizza, V.G. .... 59

Madopar HBS: Slow-Release Levodopa and Benserazide in Parkinsonian Patients Presenting Marked Fluctuations in Symptoms on Standard L-Dopa Treatment
Jensen, N.H.; Dupont, E.; Hansen, E.; Mikkelsen, B.; Mikkelsen, B.0 ................................................................................. 68

Open Clinical Study of Madopar HBS
Ludin, H.P. ....................................................................................................................... 73

VI

Contents

Treatment of Parkinsonian Conditions with a Controlled-Release Form of Levodopa - Preliminary Study
Nordera, G.P.; Lotzino, A.; Lion, P.; Durisotti, C; D’Andrea, G.; Ferro-Macario, F ............................................ 76

Preliminary Experience with Madopar HBS: Clinical Observations and Plasma Levodopa Concentrations
Fischer, P.-A.; Baas, H. ........................................................................................................ 81

Open Multicenter Trial with Madopar HBS in Parkinsonian Patients. Preliminary Assessment after Short-Term Treatment
Jansen, N.H.; MeerswaL, J.D.; Heersennu, T.; Manen, J. van; Spelman, J.D. .............................................. 88

Clinical and Pharmacokinetic Observations with Madopar HBS in Hospitalized Patients with Parkinson’s Disease and Motor Fluctuations
Poewe, W.H.; Lees, A.J.; Snell, G.K. ............................................................................................ 95